NO/cGMP production is important for the endogenous peripheral control of hyperalgesia during inflammation

• Published in: Nitric oxide Vol. 28; pp. 8 - 13
• Main Authors: Alves, Daniela P., da Motta, Patrícia G., Romero, Thiago R.L., Klein, André, Duarte, Igor D.G.
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 15.01.2013
• Subjects: Animals; Antinociception; Arginine - metabolism; Carrageenan - administration & dosage; cGMP; Cyclic GMP - biosynthesis; Cyclic GMP - metabolism; Dinoprostone - administration & dosage; Hyperalgesia - chemically induced; Hyperalgesia - metabolism; Inflammation - chemically induced; Inflammation - metabolism; Inflammatory hyperalgesia; Male; Nitric oxide; Nitric Oxide - biosynthesis; Nitric Oxide - metabolism; Pain - chemically induced; Pain - metabolism; Pain Measurement; Pressure; Rats; Rats, Wistar; Antinociception; cGMP; Nitric oxide; Inflammatory hyperalgesia
• ISSN: 1089-8603; 1089-8611
• DOI: 10.1016/j.niox.2012.09.001

► Peripheral NO/cGMP endogenous control of inflammatory pain was investigated. ► NO-Arg and MB reduced the nociceptive threshold of carrageenan-induced hyperalgesia. ► Zaprinast and l-arginine counteracted carrageenan-induced hyperalgesia. ► Peripheral activation of the NO/cGMP pathway modulates inflammatory hyperalgesia. Various studies have demonstrated the role of the nitric oxide (NO)/cGMP pathway in pain processing. Our group has also shown that this system participates in opioid-induced antinociception during peripheral inflammation. We have previously observed that inflammation mobilizes an endogenous opioidergic system to control hyperalgesia. Here, we investigated whether the NO/cGMP pathway underlies peripheral endogenous nociception control during inflammation. In this study, a pharmacological approach was used in conjunction with the rat paw pressure test to assess the effects of intraplantar NO synthase inhibitor NG-Nitro-l-arginine (NOArg), guanylyl cyclase inhibitor methylene blue (MB), phosphodiesterase-5 inhibitor zaprinast (ZP), or NO precursor l-arginine injection on carrageenan-induced hyperalgesia, which mimics an inflammatory process, or by prostaglandin E2 (PGE2), which directly sensitizes nociceptors. Intraplantar carrageenan (62.5, 125, 250 or 500μg) or PGE2 (0.1, 0.5 or 2μg) administration produced hyperalgesia, which manifested as a reduction in the rat nociceptive threshold to mechanical stimuli. NOArg (25, 50 or 100μg/paw) and MB (125, 250 or 500μg/paw) induced significant and dose-dependent reductions in the nociceptive threshold of carrageenan-induced (125μg/paw) hyperalgesia, but not PGE2-induced (0.5μg/paw) hyperalgesia. This was a local effect because it did not produce any modifications in the contralateral paw. Both Zaprinast (100, 200 or 400μg/paw) and l-arginine (100, 200 or 400μg/paw) significantly counteracted carrageenan-induced hyperalgesia (250μg/paw), yielding an increase in the nociceptive threshold compared with the control. Zaprinast (200μg/paw) or l-arginine (400μg/paw) did not produce an antinociceptive effect in the contralateral paw, indicating local action. In addition, at the same dose that was able to modify carrageenan-induced hyperalgesia, neither zaprinast nor l-arginine modified PGE2 (2μg) injection-induced hyperalgesia of the rat paw. Taken together, these results indicate that the l-arginine/NO/cGMP pathway functions as an endogenous modulator of peripheral inflammatory hyperalgesia.